CARDIOLITE Drug Patent Profile

Which patents cover Cardiolite, and what generic alternatives are available?

Cardiolite is a drug marketed by Lantheus Medcl and is included in one NDA.

The generic ingredient in CARDIOLITE is technetium tc-99m sestamibi kit. There are four drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the technetium tc-99m sestamibi kit profile page.

Summary for CARDIOLITE

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Clinical Trials:	10
Drug Prices:	Drug price information for CARDIOLITE
What excipients (inactive ingredients) are in CARDIOLITE?	CARDIOLITE excipients list
DailyMed Link:	CARDIOLITE at DailyMed

See drug prices for CARDIOLITE

Recent Clinical Trials for CARDIOLITE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
National Cancer Institute (NCI)	Early Phase 1
GE Healthcare	Early Phase 1
M.D. Anderson Cancer Center	Early Phase 1

See all CARDIOLITE clinical trials

US Patents and Regulatory Information for CARDIOLITE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Lantheus Medcl	CARDIOLITE	technetium tc-99m sestamibi kit	INJECTABLE;INJECTION	019785-001	Dec 21, 1990	AP	RX	Yes	Yes

Expired US Patents for CARDIOLITE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Lantheus Medcl	CARDIOLITE	technetium tc-99m sestamibi kit	INJECTABLE;INJECTION	019785-001	Dec 21, 1990	4,452,774
Lantheus Medcl	CARDIOLITE	technetium tc-99m sestamibi kit	INJECTABLE;INJECTION	019785-001	Dec 21, 1990	5,324,824
Lantheus Medcl	CARDIOLITE	technetium tc-99m sestamibi kit	INJECTABLE;INJECTION	019785-001	Dec 21, 1990	4,988,827*PED
Lantheus Medcl	CARDIOLITE	technetium tc-99m sestamibi kit	INJECTABLE;INJECTION	019785-001	Dec 21, 1990	4,885,100
Lantheus Medcl	CARDIOLITE	technetium tc-99m sestamibi kit	INJECTABLE;INJECTION	019785-001	Dec 21, 1990	4,894,445

International Patents for CARDIOLITE

See the table below for patents covering CARDIOLITE around the world.

Country	Patent Number	Title	Estimated Expiration
Ireland	863353
Mexico	168821	PROCEDIMIENTO PARA LA PREPARACION DE ISONITRILOS SUSTITUIDOS CON ETER
European Patent Office	0211424	METAL-ISONITRILE ADDUCTS FOR PREPARING RADIONUCLIDE COMPLEXES
Greece	3000681
World Intellectual Property Organization (WIPO)	8303761

Supplementary Protection Certificates for CARDIOLITE

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0107734	93C0042	Belgium		PROD. NAME TETRAKIS (2-METHOXY-ISOBUTYL-ISONITRILE). CUIVRE (I) TETRAFLUOROBORATE, DIHYDRATE DE CHLORURE STANNEUX, CHLORHYDRATE DE L-CYSTEINE (MONOHYDRATE); REG NO/DATE 923 IS 3 F 12/ 19900924 ; FIRST REG CC NO DATE IE PA 200/9/1 19900817
1178838	300736	Netherlands		PRODUCT NAME: TILMANOCEPT, DESGEWENST GELABELD MET TECHNETIUM TC 99M; REGISTRATION NO/DATE: EU/1/14/955 20141119
0107734	SPC/GB93/166	United Kingdom		SPC/GB93/166, EXPIRES: 20050816

CARDIOLITE Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory of Cardiovascular Drugs: A Focus on the Broader Market

Introduction to the Cardiovascular Drugs Market

The global cardiovascular drugs market is a robust and expanding sector within the pharmaceutical industry. This market is driven by several key factors, including the increasing prevalence of heart-related conditions, advancements in drug formulations, and the aging population.

Market Size and Growth Projections

As of 2023, the global cardiovascular drugs market was valued at USD 144.11 billion and is projected to grow to USD 207.78 billion by 2033, with a Compound Annual Growth Rate (CAGR) of 4% from 2024 to 2033[1].

Key Drivers of the Market

Increasing Prevalence of Cardiovascular Diseases

The rising incidence of heart-related conditions such as arrhythmias, coronary artery disease, hypertension, and heart failure is a significant driver of the market. These conditions are becoming more prevalent due to lifestyle factors and the aging population[1][3][4].

Advancements in Drug Formulations

Continuous innovation in drug formulations and the introduction of new therapies are crucial for market growth. For instance, the introduction of new cardiology drugs like acoramidis by Bayer highlights the ongoing research and development efforts in this field[1].

Aging Population

The aging population is a major driver, as older adults are more prone to cardiovascular diseases. The demographic shift towards an older population is expected to continue, thereby increasing the demand for cardiovascular drugs[3][4].

Market Segmentation

By Drug Type

The anticoagulants segment holds the highest market share, accounting for approximately 45.14% of the market in 2023. This segment is expected to continue its dominance due to the critical role anticoagulants play in managing cardiovascular conditions[1].

By Route of Administration

The oral segment captures a significant revenue share, with around 54.84% of the market in 2023. Oral drugs are preferred due to their ease of administration and patient compliance[1].

Geographical Distribution

Asia Pacific

The Asia Pacific region holds the highest market share, with around 34.17% in 2023. This is largely due to the aging population and rising health expectations in countries like China, which are driving the demand for cardiovascular drugs[1].

North America and Europe

North America and Europe are also significant markets, driven by the high prevalence of cardiovascular diseases and advanced healthcare infrastructure. These regions are expected to contribute substantially to the market growth[3][4].

Major Breakthroughs and Acquisitions

Bayer's Acquisition of Acoramidis

Bayer's acquisition of exclusive commercialization rights for acoramidis, a drug for transthyretin amyloid cardiomyopathy (ATTR CM), is a strategic move that strengthens its cardiovascular portfolio[1].

Novo Nordisk's Acquisition of Cardior Pharmaceuticals

Novo Nordisk's acquisition of Cardior Pharmaceuticals for up to 1.025 billion Euros highlights the ongoing consolidation and innovation in the cardiovascular drugs market[1].

Financial Performance and Investment Trends

Revenue and Profitability

Companies in the cardiovascular drugs market have shown significant revenue growth. For example, Lantheus Holdings, a company involved in precision diagnostics and radiopharmaceuticals, reported revenues of $92.509 million in the first quarter of 2021, with a net income of $9.008 million[2].

Investment and M&A Activities

The market has seen substantial investment and merger and acquisition activities. Venture capitalists and pharmaceutical companies are keen on acquiring assets that can drive sales and innovation in the cardiovascular space. Recent deals, such as Novartis's acquisition of The Medicines Co. and Bristol Myers Squibb's acquisition of MyoKardia, demonstrate the high value placed on promising cardiovascular drugs[5].

Challenges and Opportunities

Venture Capital and M&A

Despite the potential, venture-backed companies face challenges in entering the cardiovascular market due to uncertainty about future M&A possibilities. However, successful deals can incentivize further investment and the formation of new companies[5].

Unmet Needs

There are still significant unmet needs in the treatment of cardiovascular diseases, such as chronic heart failure with preserved ejection fraction, which presents a $7 billion market opportunity. Addressing these needs could drive further innovation and investment[5].

Illustrative Statistics

• Global Market Size: The global cardiovascular drugs market was valued at USD 144.11 billion in 2023 and is projected to reach USD 207.78 billion by 2033[1].
• CAGR: The market is expected to grow at a CAGR of 4% from 2024 to 2033[1].
• Segment Share: Anticoagulants hold around 45.14% of the market share by drug type[1].
• Geographical Share: Asia Pacific holds around 34.17% of the market share[1].

Expert Insights

"The aging population represents a significant driving force behind the surge in demand for Congestive Heart Failure (CHF) drugs within the Global Congestive Heart Failure Drugs Market. As people worldwide are living longer, they are more prone to cardiovascular diseases, with CHF being a particularly prevalent and challenging condition among the elderly."[3]

Key Takeaways

• The global cardiovascular drugs market is poised for significant growth driven by increasing prevalence of heart-related conditions and advancements in drug formulations.
• The aging population and lifestyle-related risk factors are key drivers of the market.
• Anticoagulants and oral drugs are dominant segments in the market.
• Asia Pacific, North America, and Europe are significant geographical markets.
• Recent acquisitions and investments highlight the market's potential for innovation and growth.

Frequently Asked Questions (FAQs)

Q: What is the projected growth rate of the global cardiovascular drugs market from 2024 to 2033? A: The global cardiovascular drugs market is expected to grow at a CAGR of 4% from 2024 to 2033[1].

Q: Which segment holds the highest market share in the cardiovascular drugs market by drug type? A: The anticoagulants segment holds the highest market share, accounting for approximately 45.14% of the market in 2023[1].

Q: What is the impact of the aging population on the demand for cardiovascular drugs? A: The aging population is a significant driver of the market, as older adults are more prone to cardiovascular diseases, leading to an increased demand for these drugs[3][4].

Q: Which region holds the highest market share in the global cardiovascular drugs market? A: The Asia Pacific region holds the highest market share, with around 34.17% in 2023[1].

Q: What are some of the recent significant acquisitions in the cardiovascular drugs market? A: Recent acquisitions include Bayer's acquisition of acoramidis and Novo Nordisk's acquisition of Cardior Pharmaceuticals[1].

Cited Sources

1. Biospace: "Cardiovascular Drugs Market Size to Worth USD 207.78 billion by 2033"[1]
2. Lantheus Holdings: "United States Securities and Exchange Commission"[2]
3. Techsciresearch: "Congestive Heart Failure Drugs Market By Size, Growth, Trends and Forecast"[3]
4. Fortune Business Insights: "Cardiovascular Drugs Market Size, Share, Growth | Global Report"[4]
5. Biopharmadive: "Pharmacquired: Splashy deals belie a shallow pool of heart drugs"[5]